Expert Insights Into the Management of MPNs : Episode 12
News
Video
Considering Toxicities and Side Effects of JAK Inhibitors in Patients with MF
Author(s):
Abdulraheem Yacoub, MD, details the side effect profiles of the approved JAK inhibitors for myelofibrosis treatment.
EP: 1.An Overview of Myeloproliferative Neoplasms (MPNs)
EP: 2.Risk Assessment for Patients with Polycythemia Vera (PV)
EP: 3.Current Treatment Landscape for Patients With PV
EP: 4.Selecting a Frontline Therapy for Patients With PV
EP: 5.Ruxolitinib for the Management of PV
EP: 6.Ropeginterferon alfa-2b for the Treatment of PV
EP: 7.Reviewing the Types of Myelofibrosis
EP: 8.The Role of Transplant in the Treatment of Patients With MF
EP: 9.COMFORT-I and COMFORT-II Data Review
EP: 10.Pacritinib and Fedratinib for the Treatment of MF
EP: 11.Sequencing Therapies in Patients with MF
Now Viewing
EP: 12.Considering Toxicities and Side Effects of JAK Inhibitors in Patients with MF
EP: 13.Symptom Monitoring in Patients with MF
EP: 14.Exploring the Future of MF Treatment
Related Videos
Related Content
